search
Back to results

Collaborative Network to Take Responsibility for Oral Anticancer Therapy (CONTACT)

Primary Purpose

Breast Cancer, ALL, Lung Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Implementation of a care pathway
Sponsored by
KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Breast Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • a hematological cancer of solid tumor
  • starting an oral anticancer drug for the first time
  • able to understand and speak Dutch

Exclusion Criteria:

  • patients following an adjuvant oral anticancer therapy (e.g. tamoxifen)
  • patients following a therapy with a study drug

Sites / Locations

  • AZ TurnhoutRecruiting
  • Maria Middelares GentRecruiting
  • Imelda BonheidenRecruiting
  • AZ Groeninge KortrijkRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Non-care pathway

Care Pathway

Arm Description

This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician.

This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician.

Outcomes

Primary Outcome Measures

Change in self-management skills
There is no gold standard to define self-management. A definition from Barlow et al., 2002 (2) defines self-management as follows: the ability of an individual to manage the symptoms, treatment, physical and psychosocial consequences and life style changes due to his/her condition. Adequate self-management refers to the ability to monitor one's condition and to effect cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality of life. The studied self-management skills in this project comprise "social integration and support", "health service navigation", "constructive attitudes and approaches", "skill and technique acquisition" and "emotional distress".

Secondary Outcome Measures

Change in medication Adherence
Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ)
Change in patient satisfaction with care using Out-patsat 35
The outpatsat is a questionnaire for ambulatory cancer patients in which they are asked to rate in different subscales their perceptions on care delivered by doctors, nurses and rate te overall organisation (accessibility of the hospital, ease of reaching the hospital by telephone, ...) during their stay at day hospital of consultations
Health Related Quality of Life
Change in Distress using the Distress Barometer
Efficacy of treatment Using ECOG performance scale and RECIST criteria
Toxicity of treatment
Summarizing adverse drug events
Cost of care
Prospective report on health care expenditures (use of healthcare and other services, use of medicines, …)

Full Information

First Posted
August 2, 2016
Last Updated
April 15, 2019
Sponsor
KU Leuven
search

1. Study Identification

Unique Protocol Identification Number
NCT02861209
Brief Title
Collaborative Network to Take Responsibility for Oral Anticancer Therapy
Acronym
CONTACT
Official Title
CONTACT: A Prospective Interventional Multicentre Before-after Study for the Implementation of a Care Pathway to Increase Self-management of Patients With Cancer Who Are Treated With Oral Anticancer Medications
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
November 2015 (undefined)
Primary Completion Date
November 2022 (Anticipated)
Study Completion Date
November 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
KU Leuven

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD). The care pathway will be developed in six hospitals in Flanders, and will be adapted to the local setting and situation. The investigators hypothesize that the implementation of a care pathway will increase the quality of the drug therapy, the communication between health care professionals (HCPs) and patients, and will lead to an improved level of self-management and adherence. Moreover, the invesitgators hypothesize that the care pathway will facilitate the communication between HCPs in the hospital setting and in ambulatory care, and will improve counseling skills, self-efficacy and self-confidence of HCPs. At the end of the study, a roadmap for the nation-wide implementation of a similar care pathway will be constructed based on the experiences of the participating hospitals. This roadmap will certainly include an e-learning platform for healthcare professionals.
Detailed Description
For each hospital, an individual care pathway will be developed following the 7-phase model by Vanhaecht et al., 2011. This methodology aims to offer a systematic approach in 7 phases for the support of an interdisciplinary team in the development of new care pathways or in the improvement of existing ones. The before-part of the study includes phases 1 to 4 that aim to map current practice in detail and to translate these findings into the development of a care pathway. Current practice will be investigated using mixed methods comprising: surveys evaluating care on the level of the hospital semi-structured interviews with healthcare professionals (HCP) and patients outcome assessments in patients included in the study (self-management, adherence, satisfaction with care, satisfaction with information, quality of life) using validated questionnaires at the start of the therapy, after 1 month and after three months outcome assessments in healthcare professionals at baseline (self-efficacy and perceptions on self-management) using validated questionnaires training and feedback sessions on counseling for HCPs Based upon these findings, a care pathway in each hospital will be developed by a local project team of different stakeholders from different disciplines. The after-part of the study includes phase 5-7 in which the care pathway is implemented, evaluated and continuously followed up. Implementation and evaluation take place at the same time. The evaluation includes: outcome assessments in patients (newly recruited) at the start of the therapy, after 1 month and after three months outcome assessments in HCPs (follow up) evaluation of counseling skills focus group discussions and interviews with HCPs to evaluate the development and implementation of the care pathway. At the end of the study a comparison of outcomes before and after the implementation will be made to study the impact of the care pathway on the before mentioned aspects (see "Brief Summary").

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, ALL, Lung Cancer, Melanoma, Colorectal Cancer, Prostate Cancer

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
228 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Non-care pathway
Arm Type
No Intervention
Arm Description
This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician.
Arm Title
Care Pathway
Arm Type
Experimental
Arm Description
This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months. The decision to start with an oral anticancer therapy depends solely on the treating physician.
Intervention Type
Other
Intervention Name(s)
Implementation of a care pathway
Intervention Description
The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
Primary Outcome Measure Information:
Title
Change in self-management skills
Description
There is no gold standard to define self-management. A definition from Barlow et al., 2002 (2) defines self-management as follows: the ability of an individual to manage the symptoms, treatment, physical and psychosocial consequences and life style changes due to his/her condition. Adequate self-management refers to the ability to monitor one's condition and to effect cognitive, behavioural and emotional responses necessary to maintain a satisfactory quality of life. The studied self-management skills in this project comprise "social integration and support", "health service navigation", "constructive attitudes and approaches", "skill and technique acquisition" and "emotional distress".
Time Frame
at the start of the therapy, after one and three months
Secondary Outcome Measure Information:
Title
Change in medication Adherence
Time Frame
after one and three months of therapy
Title
Change in patient satisfaction with treatment using the Cancer Therapy Satisfaction Questionnaire (CTSQ)
Time Frame
after one and three months
Title
Change in patient satisfaction with care using Out-patsat 35
Description
The outpatsat is a questionnaire for ambulatory cancer patients in which they are asked to rate in different subscales their perceptions on care delivered by doctors, nurses and rate te overall organisation (accessibility of the hospital, ease of reaching the hospital by telephone, ...) during their stay at day hospital of consultations
Time Frame
at the start of the therapy, after one and three months
Title
Health Related Quality of Life
Time Frame
at the start of the therapy, after one and three months
Title
Change in Distress using the Distress Barometer
Time Frame
at the start of the therapy, after one and three months
Title
Efficacy of treatment Using ECOG performance scale and RECIST criteria
Time Frame
at the start of the therapy, after one and three months
Title
Toxicity of treatment
Description
Summarizing adverse drug events
Time Frame
at the start of the therapy, after one and three months
Title
Cost of care
Description
Prospective report on health care expenditures (use of healthcare and other services, use of medicines, …)
Time Frame
at the start of the therapy, after one and three months
Other Pre-specified Outcome Measures:
Title
Change in Self-efficacy in HCPs using the Self-efficacy and Performance in Self-management Instrument (SEPSS)
Description
SEPSS investigates the ability of a HCP to evaluate their own performance in daily practice and caregiving.
Time Frame
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)
Title
Change in perceptions on self-management in HCPs using the Clinician Support for Patient activation measure
Time Frame
at baseline (before the implementation of the care pathway) and after 24 months (during implementation)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: a hematological cancer of solid tumor starting an oral anticancer drug for the first time able to understand and speak Dutch Exclusion Criteria: patients following an adjuvant oral anticancer therapy (e.g. tamoxifen) patients following a therapy with a study drug
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lise-Marie Kinnaer, PharmD
Phone
3216328265
Email
lisemarie.kinnaer@kuleuven.be
First Name & Middle Initial & Last Name or Official Title & Degree
Veerle Foulon, Prof. Dr.
Email
veerle.foulon@kuleuven.be
Facility Information:
Facility Name
AZ Turnhout
City
Turnhout
State/Province
Antwerpen
ZIP/Postal Code
2300
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise-Marie Kinnaer, PharmD
Phone
16328265
Ext
32
Email
lisemarie.kinnaer@kuleuven.be
Facility Name
Maria Middelares Gent
City
Ghent
State/Province
Oost-Vlaanderen
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise-Marie Kinnaer, PharmD
Phone
16328265
Ext
32
Email
lisemarie.kinnaer@kuleuven.be
Facility Name
Imelda Bonheiden
City
Bonheiden
State/Province
Vlaams-Brabant
ZIP/Postal Code
2820
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise-Marie Kinnaer, PharmD
Phone
16328265
Ext
32
Email
lisemarie.kinnaer@kuleuven.be
Facility Name
AZ Groeninge Kortrijk
City
Kortrijk
State/Province
West-Vlaanderen
ZIP/Postal Code
8000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise-Marie Kinnaer, PharmD
Phone
016328265
Ext
32
Email
lisemarie.kinnaer@kuleuven.be
First Name & Middle Initial & Last Name & Degree
Veerle Foulon, Prof. Dr.
Email
veerle.foulon@kuleuven.be

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31310353
Citation
Kinnaer LM, Decoene E, Van Hecke A, Foulon V. Collaborative network to take responsibility for oral anticancer therapy (CONTACT): Study-protocol investigating the impact of a care pathway. J Adv Nurs. 2019 Dec;75(12):3726-3739. doi: 10.1111/jan.14157. Epub 2019 Aug 27.
Results Reference
derived

Learn more about this trial

Collaborative Network to Take Responsibility for Oral Anticancer Therapy

We'll reach out to this number within 24 hrs